Open Access Full Text Article

REVIEW

821

A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions

Naghmeh Foroutan^{1,2} Jean-Eric Tarride¹⁻³ Feng Xie^{1,3,4} Mitchell Levine¹⁻³

¹Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada; ²Programs for Assessment of Technology in Health (PATH), The Research Institute of St. Joe's, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada; ³Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, ON, Canada; ⁴Program for Health Economics and Outcome Measures (PHENOM), Hamilton, ON, Canada

Correspondence: Naghmeh Foroutan McMaster University, CRL Building, Main Street West, Hamilton, ON, Canada, L8S 4K1

Tel: +1 905 525 9140 ext 20210 Email foroutn@mcmaster.ca



Introduction: Budget impact analysis (BIA) in health care, sometimes referred to as resource impact, is the financial change in the use of health resources associated with adding a new drug to a formulary or the adoption of a new health technology. Several national and transnational organizations worldwide have updated their BIA guidelines in the past 4 years. The aim of the present review was to provide a comprehensive list of the key recommendations of BIA guidelines from different countries that may be of interest for those who wish to build or to update BIA guidelines.

Methods: National and transnational BIA guidelines were searched in databases including MEDLINE, EMBASE, Cochrane, EconLit, CINAHL, Business Source Premier, HealthSTAR, and the gray literature including regulatory agency websites. Data were reviewed and abstracted based on key elements in a standard BIA model (analytical model structure, input and data sources, and reporting format).

Results: Eight national (Australia, UK, Belgium, Ireland, France, Poland, Brazil, and Canada) and one transnational (International Society for Pharmacoeconomics and Outcomes Research) BIA guidelines were included in this review, and a comprehensive list of BIA recommendations was identified. The review showed that certain recommendations such as patient population assessment, drug-related direct costs, discounting, and disaggregated results were common across the various jurisdictions. BIA guidelines differed from each other in terms of the number and scope of recommendations, the terminology used (eg, the definition of comparators or cost offsets) and the direction of the recommendations (ie, to include or not to include with respect to such items as off-label indications, indirect costs, clinical outcomes, and resource utilization).

Conclusion: While there was a common purpose for all of the BIA guidelines that were identified, substantial differences did occur in the specific recommendations. The pharmaceutical financing system structure might explain why guidelines from the UK, Australia, and Canada have more country-specific recommendations. The desire to be consistent with adopted economic evaluation assumptions might be another reason for some observed differences between countries. Further research is required to assess the source of the heterogeneity between BIA recommendations are identified in different guidelines.

Keywords: budgetary impact, financial impact, resource impact assessment, pharmaceutical reimbursement, new drug submissions, guidelines

Introduction

The first budget impact analysis (BIA) analytic framework was published by Mauskopf¹ in 1998. In 2001, Trueman et al² provided essential suggestions for conducting a BIA,

ClinicoEconomics and Outcomes Research 2018:10 821-854

© 2018 Foroutan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. you hereby accept the fore.commercial uses of the work are premitted without any further permission form Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.dover.dover.sc.com/terms.dover.dover.dover.dover.sc.com/terms.dover.dover.sc.com/terms.dover.dover.sc.com/terms.dover.dover.dover.sc.com/terms.dover.dover.dover.dover.dover.sc.com/terms.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.dover.av.dover.dover.dover.do and the Polish BIA guidelines in 2004³ followed the initial framework of BIA proposed by Trueman et al.² In 2005 in Canada, the Patented Medicine Prices Review Board initiated the development of the Canadian BIA guidelines which were subsequently published in 2007.⁴ The International Society For Pharmacoeconomics and Outcomes Research (ISPOR) task force published the first transnational guidelines for the execution of a BIA in 2007,⁵ followed by Germany⁶ and France⁷ in 2008.

During the past decade, many jurisdictions around the world have updated their BIA guidelines, including the Ireland (2018),⁸ France (2018),⁹ UK (2017),¹⁰ Australia (2016),¹¹ Poland (2016),¹² and Belgium (2015).¹³ ISPOR published their second task force report on good practices for conducting BIA in 2014.¹⁴ In Asia (ie, Iran,^{15–17} Thailand¹⁸) and Latin America (ie, Brazil,¹⁹ Chile, Colombia, Cuba, and Mexico), there have been initiatives regarding drug reimbursement decision making based on standard economic evaluation and BIA guidelines. Brazil has published their BIA guidelines in 2012, and Chile, Colombia and Mexico require BIA as part of their Health Technology Assessment (HTA) process.²⁰

A number of systematic reviews of BIA empirical studies have recently been published,²¹⁻²⁵ and literature reviews of national and transnational BIA guidelines have been conducted as part of national BIA guidelines development (eg, France [2018],⁹ Belgium [2015],¹³ and Canada [2008]²⁶). However, the Belgian and the Canadian guidelines did not systematically review the BIA literature. In contrast, the French BIA guidelines provides a comprehensive review of the BIA literature, including 9 national BIA guidelines, 5 recommendations of good practices developed by national and international societies for health economics, and 14 methodological publications on existing BIAs, published between 2000 and 2016.9 Nevertheless, the French review did not provide sufficient details regarding the individual guidelines reviewed and cannot be used as a foundation for constructing a new set of BIA guidelines or updating existing versions. To illustrate, the results were briefly listed in a table in an aggregated form rather than providing a complete detailed list of the BIA recommendations. The present study has been designed to identify and abstract all guideline recommendations relating to three key aspects in designing a standard pharmaceutical BIA (analytical model structure, input data and sources, and reporting format). This paper presents a comparative review of the BIA key element recommendations that are discussed in national and transnational BIA guidelines and, also, provides a list of the relevant components that are needed in order to conduct a comprehensive pharmaceutical BIA.

Methods Data sources

A systematic search of the literature was undertaken to identify BIA guidelines published from 1998 to June 30, 2018. The following bibliographic databases were searched through the Ovid interface: MEDLINE, EMBASE, Cochrane, Econ-Lit, CINAHL, Business Source Premier, and HealthSTAR. We also searched the gray literature (Supplementary material S1) including International Network of Agencies for Health Technology Assessment (INAHTA) and non-INAHTA members (eg, National Institute for Health and Care Excellence, Pharmaceutical Management Agency as well as EUnetHTA, Health Technology Assessment International, International Health Economics Association, and International Society for Pharmacoeconomics and Outcomes Research). The search strategy included a combination of text words and Medical Subject Headings terms and synonyms of budget/financial analysis, guidelines, and methodology/modeling. The keywords used for the searches are shown in Supplementary material S1.

Inclusion and exclusion criteria

The inclusion criteria were limited to BIA guidelines published since 1998 by different countries or international organizations (eg, ISPOR) that presented recommendations on all three key elements of designing a BIA (ie, analytical model structure, input and data sources, and reporting format).¹⁴ The titles and abstracts identified in these searches were screened to find eligible published national and transnational BIA guidelines (peer-reviewed or online multimedia). When a country or transnational BIA guideline was updated, we only included the latest updated version of the BIA guidelines for each organization in order to avoid duplication in data abstraction.

Citations that reported BIA for any specific drug or medical device (empirical studies), or review articles of empirical BIAs, abstracts, and conference proceedings and methodological publications other than guidelines for conducting a pharmaceutical BIA were excluded. National guidelines were excluded if they did not explicitly discuss the key elements of a BIA model or if they did not add any additional information beyond the guideline that had been adopted from, and where the latter was already included in the review.

Study selection, data abstraction, and synthesis

Titles and abstracts of all articles were screened (level 1 screening) for inclusion by one reviewer. Following level 1 screening, the full text of the selected articles was retrieved

(level 2 screening) and assessed by two independent reviewers for eligibility for final inclusion. The disagreement was resolved through consensus and, if persistent, arbitrated through discussion with a third person.

Using a data abstraction template, all included guidelines were reviewed by two independent reviewers to abstract key elements which were discussed in each BIA guideline. An Excel-based data abstraction form was developed based on the predetermined BIA key elements in accordance with ISPOR BIA guidelines (For sake of simplicity and consistency with other BIA guidelines, in the present review, "ISPOR II Task Force report on BIA Good Practice" was abbreviated to "ISPOR BIA guidelines").¹⁴ All the listed recommendations were for a base-case BIA model. The Excel-based data abstraction form was initially tested using two (Irish and Belgian) BIA guidelines before being used to abstract the data/recommendations from all the included BIA guidelines.

For the purpose of this paper, the BIA key elements were categorized into three groups: analytic model structure, input and data sources, and the reporting format. In each category, we defined primary and secondary elements. The primary elements were the main components within each category (eg, perspective, time horizon, target population, scenarios to compare, costing, modeling, and uncertainty), and secondary elements were more specific and detailed considerations related to the primary elements (eg, off-label use, the degree of implementation, and scenario analysis). The analytic model structure contains a discussion of twelve primary BIA elements (eg, model design, model validation, perspective, time horizon, target population, costing, comparators, discounting and inflation, and handling the uncertainty). The data input category mainly addresses data sources for market-share estimation and epidemiologic analyses. The reporting format section describes details for reporting BIA results based on the payer's requirements and the standard practices in conducting and reporting BIAs (eg, aggregated and disaggregated results in each year of the time horizon and outcomes are presented in natural and monetary units). All terminologies, categories, and BIA key elements were defined in accordance with ISPOR BIA guidelines.14

Results

Literature search results

A total of 3,804 potential citations were identified through the systematic and the manual searches (having removed duplicates). Fifty-two citations were included after the title and abstract review, of which 43 were excluded for not meeting the eligibility criteria, resulting in a total of 9 national and transnational BIA guidelines published between 1998 and 2018.^{8–14,19,26} Figure 1 shows the detailed study selection process, and a summary of the included guidelines in the review is shown in Table 1.

Country-specific (national) guidelines from eight countries (Australia, UK, Belgium, Ireland, France, Poland, Brazil, and Canada) were included. The guidelines from five countries were excluded. Germany (2008),⁶ Thailand (2014),¹⁸ and the USA²⁷ each adopted the ISPOR BIA guidelines, while the Wales²⁸ and Scotland²⁹ guidelines were derived from the UK NICE recommendations.¹⁰ None of these five countries provided any additional methodological information beyond the source guidelines that they had adopted (which were already included in this review as a primary guideline). A summary of the countries that have developed national BIA guidelines and their associated drug plans is provided in Supplementary material S2.

Guideline recommendations pertaining to the BIA key elements

A comprehensive list of all the BIA guideline recommendations was derived from the nine reviewed guidelines and is presented in Table 2. Figure 2 shows the number of guidelines that have made specific recommendations. The following sections provide a synthesis of the key similarities and differences among the nine guidelines.

Analytical model structure Perspective

In most BIAs, using the perspective of the primary health care budget holder is recommended. However, in the French,⁹ Polish,¹² and Canadian²⁶ BIA guidelines there is a recommendation to use the patient's perspective as complementary analysis to the base-case analysis. In contrast, Australia¹¹ explicitly requires the exclusion of any copayment from any other source beyond the identified budget.

Time horizon

It is recommended in the Polish¹² and Belgian¹³ guidelines to present the budget impact up to the steady state, with a minimum time horizon of 2–3 years. The minimum time horizon in the Canadian BIA guidelines²⁶ is 3 years, whereas in the updated NICE¹⁰ and Australian¹¹ guidelines a longer time duration is recommended (6 and 5 years, respectively). France⁹ and ISPOR¹⁴ recommend a BIA time horizon varying from 3–5 and 1–5 years in the base-case analysis, respectively.




Figure I PRISMA flow diagram of search results.

Abbreviations: BIA, budget impact analysis; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

The Brazilian guidelines have also taken a time horizon from 1–5 years.¹⁹ The base-case analysis should estimate the annual financial impact over a minimum timeframe of 5 years in the recently updated Irish guidelines.⁸ A comparison of the time horizon recommended in different guidelines is shown in Figure 3.

Target population

Some guidelines have defined the target population as the "entire population of patients affected by the assessed indications, targeted by the proposed medicine, over a specified time horizon.^{8,12,14} French guidelines have introduced two population groups to be included in the analysis, "the target population and the expected treated (forecasted population to be actually treated by the intervention in the real-life practice) population for all indications."⁹ Based on the Canadian BIA guidelines, the target population is defined as "all drug plan beneficiaries who are expected to be diagnosed and treated for the conditions of interest and are eligible to use the new drug."²⁶

Subpopulation analyses can be performed for BIA if there are appropriate justifications: by beneficiary, differences in safety, treatment effect, baseline risks, costs, or market share.^{8,9,11,13,14,19} For the target population estimation, there are two approaches: top-down or epidemiological and bottom-up or market-share (claim-based analyses). An epidemiological approach is usually preferred if the submission indicates a superior therapeutic conclusion in clinical studies, whereas a market-share approach might be preferred if the submission indicates a noninferior therapeutic conclusion.¹¹ In the epidemiological approach, disease severity shifts, incidence, and prevalence are required, and it is usually inevitable to use data from different sources.²⁶ Apart from the UK,¹⁰ Poland,¹² and ISPOR¹⁴ (which only ask for the epidemiologic approach), other guidelines recommend BIA results obtained from both epidemiologic and market-share approaches for all new drug submissions.

The degree of implementation (full replacement or partial substitution of existing technologies or shifts in the target

Countries	Financing system	Year	Organization	Title
Ireland ⁸	Publicly funded	2018	The Health Information	Guidelines for the Budget Impact Analysis
	health and social care		and Quality Authority	of Health Technologies in Ireland 2018
	system		(the authority)	
France ⁹	French statutory	2018	HAS	The HAS guidelines for conducting BIA
	social insurance			
	scheme			
UK¹⁰	NHS	2017	NICE	Assessing resource impact process manual: guidelines
Australia ¹¹	PBS	2016	PBAC	Guidelines for preparing a submission to the PBAC (version 5.0)
Poland ¹²	National Health Fund	2016	The Agency for Health	HTA guidelines
	(NHF)		Technology Assessment	
			and Tariff System	
Belgium ¹³	Federal government,	2015	Belgian Health Care	Guidelines for BIAs
	communities, patients		Knowledge Centre	
ISPOR ¹⁴	NA	2014	ISPOR	ISPOR taskforce report: Budget Impact
				Analysis – Principles of good practice:
				Report of the ISPOR 2012 Budget Impact
				Analysis good practice II task force
Brazil ¹⁹	Unified Health	2012	Ministry of Health,	Diretriz para análises de impacto
	System		National Committee	orçamentário de tecnologias em saúde
			for Health Technology	no Brasil (guidelines for budget impact
			Incorporation	analysis of health technologies in Brazil)
Canada ²⁶	Federal, provincial	2007	Patented Medicine	Guidelines for conducting pharmaceutical
	and territorial drug		Prices Review Board	budget impact Analyses for submission to
	plans, private payers,			public drug plans in Canada
	patients			

Table I Summary of nine included guidelines in the review

Abbreviations: BIA, budget impact analysis; HAS, French National Authority for Health; HTA, health technology assessment; ISPOR, International Society for Pharmacoeconomics and Outcomes Research; NHS, National Health System; NA, not applicable; NICE, National Institute for Health and Care Excellence; PBAC, Pharmaceutical Benefits Advisory Committee; PBS, Pharmaceutical Benefits Scheme; RIA, resource impact assessment.

population, market growth, or expansion) is essential in both approaches and recommended by most guidelines. In the Canadian guidelines, it is advised that the treatment displacement assumptions regarding the changes to the market share of each competitor after the introduction of the new drug be tested in the sensitivity analysis.²⁶ The population is dynamic in the Irish, Polish, Belgian, ISPOR and Brazilian guidelines, meaning that patients could be added to or removed from the analysis based on whether they meet the inclusion criteria or not over time.^{8,12–14,19} In some cases, when the technology applies to a well-defined group of patients, the BIA may require a defined closed population.¹²

In addition, the French, Belgian, ISPOR (for the current treatment mix) and Brazilian BIA guidelines^{9,13,14,19} recommend consideration of off-label usage in all indications for the assessed medicine as complementary to the base- case analysis; this is especially relevant if there is available evidence for cost-effectiveness and, more importantly, it is

noted by the payer.⁹ In the Canadian BIA guidelines, the off-label use is only considered in the sensitivity analysis.²⁶ The catch-up effect which applies to the chronic conditions for patients who switch to the new drug is recommended in the Irish and ISPOR guidelines.^{8,14} Any planned local regulations and legislations which would limit new drug access in a subpopulation should be considered.^{12,14,19,26}

Scenarios to compare (comparators)

In most of the reviewed guidelines, the current scenario/ practice (including "no intervention") should be "routine care" or the best clinical practice, including the most costeffective alternatives. The new scenario is the "current scenario" with the new intervention added to or replacing the current interventions entirely or partially.^{13,14} NICE considers a broader picture of budget impact and defines the current and new scenarios as current and future clinical practice activities (at activity levels) resulting from adopting

BIA primary elements	BIA secondary	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	elements									
Perspective										
	The	Yes	Yes (federal,	Yes (health	Yes (French	Yes (publicly	Yes (public	Yes	Yes (PBS/	Yes (public
	recommended		provincial,	care payers,	statutory	funded health	payers,	(commissioner,	RPBS; federal	and private
	perspective		and territorial	patients,	social	and social	patients,	provider)	government;	systems;
	is that of the		drug plans,	provider)	insurance	care system)	hospitals)		(din	nation,
	budget holder		private payers)		scheme,					states, or
	range from a				patient,					municipalities)
	single payer				provider)					
	covering an									
	entire health									
	care system									
	through									
	specific									
	providers									
Technology										
	The technology					Yes				
	should be									
	described in									
	sufficient detail									
	to differentiate									
	it from its									
	comparators									
	and to provide									
	context for the									
	study									

Rum Biology elements Score Conta Bedgins (2015) Fance Ineland Pointed Murchia Burchia Pointed		(202									
Definition Yes (all the next proputation) Yes (all the next proputation) Yes (all the next proporoth) Yes (all the next proputation	BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
Definition Yes (angles for restrictions) Test (angles for restriction	Population size and characteristics										
eligible for intervention during the carterol of interests, intervention of intervention of interventio		Definition of patient	Yes (all patients	Yes (defined as individuals		Yes (target and expected	Yes (target population	Yes (all patients in whom a	Yes (resident and registered	Yes (number of patients	Yes
interest, the horizon of interest, spin and have the condition of spin and have the interest, spin and have the interest, spin and have the interest, spi		population	eligible for the new	insured by drug plans		population)	should be defined	given health technology	population)	will be treated and number of	
uness. continuents. continuents. continuents. continuents. ofinerest. continuents. continuents. continuents. continuents. scess aread sto. continuents. continuents. continuents. scess aread sto. and sto. and sto. continuents. aread sto. and sto. indications) indications) indications) restrictions) aread sto. and sto. and sto. indications) restrictions) aread sto. and sto. indications) indications) restrictions) aread sto. and sto. aread sto. indications) restrictions) aread sto. indications) indications) indications) restrictions) aread sto. indications) indications) indications) restrictions aread sto. restrictions indications) indications) restrictions aread sto. restrictions indications) indications restrictions aread sto. restrictions restrictions indications restrictions restrictions restrictions restrictions restrictions restrestrictions resendered restredience- <td></td> <td></td> <td>intervention</td> <td>of interest and have the</td> <td></td> <td></td> <td>based on the</td> <td>can be used in accordance</td> <td></td> <td>unit doses will he dispensed</td> <td></td>			intervention	of interest and have the			based on the	can be used in accordance		unit doses will he dispensed	
of interest. interest. interest. interest. horron). access and slos and slos and slos and slos horron). access textrictions) and slos and slos and slos horron). access textrictions) a specified defined as horron). access textrictions a specified defined as horron). access textrictions a specified defined as horron). access textrictions a specified defined textrictions access textrictions a specified textrictions textrictions access textrictions textrictions textrictions textrictions file textrictions textrictions textrictions textrions			time horizon	condition of			indication	with the		over the time	
restrictions) restrictions rest			of interest,	interest)			for the	assessed		horizon)	
restrictions) restrictions) restrictions			access				and also	indications)			
Yes Yes Yes Image: Section of the disease with a specified disease who may avail of the disease who may avail of the technology being considered in the defined time horizon) Yes Yes Yes Yes Image: Section of the defined disease who may avail of the technology being considered in the defined time horizon) Yes Yes Yes Yes Image: Section of the defined disease who may avail of the technology being considered in the defined dimension of the defined dimension o			restrictions)				defined as				
Yes Yes (incidence of the certified disease who may have approach) app							those with				
Tes Mease Mo may arail of the technology arail of the technology being Considered in the defined met horizon) Tes Yes Approach) Pesed Approach) paredemice- Approach) approach) Approach) Approach)							a specified				
Yes Yes Yes Yes Yes Yes Yes Yes (incidence and (epidemiologic and approach)) approach)							disease				
Yes Yes Yes Yes ime horizon) rime horizon) Yes Yes approach) rime horizon) Pes Yes approach) approach) approach) based							who may				
Test Test Test Test Yes Yes Yes Yes Image: A substance of the defined time horizon) Test Yes Image: A substance of time horizon) Yes Yes Approach) Approach) Approach) Approach Approach) Approach)							avail of the				
Yes Yes Yes Yes Yes Yes Yes Yes approach) Ast Yes Yes approach) Ast Yes Yes							technology heine				
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Imme horizon) Imme horizon) Imme horizon) Imme horizon Imme horizon Yes Yes Yes Yes Imme horizon Imme horizon Imme horizon Imme horizon Imme horizon Yes Yes Yes Yes Imme horizon Imme horizon Imme horizon Imme horizon Imme horizon Imme horizon Imme horizon Imme horizon<							considered in				
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes approach) approach approach) base approach approach) approach) approach)							the defined				
Yes Yes Yes Yes Yes Yes Yes (epidemiologic approach) approach) base base approach) approach) approach) approach) base							time horizon)				
(epidemiologic and approach) (incidence and epidemiologic and prevalence-approach) approach)		Top-down	Yes	Yes			Yes	Yes	Yes	Yes	Yes (incidence
approach) base approach) based based approach)		population		(epidemiologic					(incidence and	(epidemiologic	and prevalence-
based based approach)		approach:		approach)					prevalence-	approach)	based
		estimation of							based		approach)
		the number							approach)		
		covered by									
		the locally									
		approved									
		for the new									
		which needs to									
		reflect untake									
		and changes in									
		patterns of use									
		_				_					(Continued)

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Bottom-up approach: this starts from the number of individuals likely to avail of the technology. It includes the number of individuals that will switch from an existing technology and the number of newly treated patients. These estimates may be informed by existing claim- based data		Yes (claim- based approach)	Yes (define population for all indications of the intervention under study)	Yes (define population for all indications of the intervention under study)	≺ ≺s	, ,		Yes (market- share approach)	Yes (claim- based approach)
	Open (dynamic) population	≺es		Yes	Yes (population should be described for each year of the BIA, and expected changes in their sizes should be taken into account)	≺es	Yes			

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Subgroups	Yes		Yes	Yes	Yes (based on biologically plausible and iustified			Yes (stratify by beneficiary)	Yes
						evidence but not based on treatment				
	Catch-up effect	Yes				response) Yes				
	Access	Yes	Yes				Yes			Yes
	Unit of analysis					Yes (per			Yes (per unit	Yes (per
	(per patient or					patient or per			dispensed)	episode)
	episode)					episode of care)				
	Off-label	Yes (for	No	Yes	Yes	No				Yes
	indications in	the current								
	the eligible	treatment								
	population	mix)								
	may also be included									
	Degree of	Yes		Yes	Yes		Yes		Yes	Yes
	implementation									
	of the new									
	intervention									
	(substitution,									
	combination,									
	and expansion)									

•	BIA	ISPOR	Canada	Belgium	France	Ireland	Poland	UK (2017)	Australia	Brazil (2012)
elements	secondary	(2014)	(2007)	(2012)	(2018)	(2018)	(2016)		(2016)	
Comparators	elements									
	Dofinition	Voc (DIA	Voc (mino	Voc (current	Vec (BIA	۲ _۵	Vac (tha			۲. د.
_						l es				
_		compares	scenarios,	situation	compares		assumptions		medicines	(comparison of
_		scenarios	reference	that would	sets of		concerning		that will be	two or more
_		defined by	and new drug	change if the	interventions		the "current		affected by	scenarios,
_		sets of, rather	scenario,	intervention	[scenarios]		scenario"		the proposed	which are
_		than specific	should be	under	rather than		and the "new		listing; mixed	representations
_		individual,	compared for	consideration	individual		scenario"		treatment	of different
_		interventions)	the treatment	is introduced	interventions)		should be		comparisons)	market
_			strategy)	in the health			described and			conditions)
_				care system;			justified in the			
_				most cost-			analysis)			
_				effective						
_				alternatives)						
	Current	Yes (the	Yes (forecast	Yes	Yes (scenarios	Yes (baseline	Yes (takes into			Yes (set of
_	intervention	current	version of		without the	scenario that	account the			therapeutic
_	mix for	mix may	the current		intervention	reflects the	interventions			options
_	the eligible	include no	market		under study)	current mix of	currently used			currently
_	population	intervention	without the			technologies	in a given			available for
_		as well as	new drug)			and forecasts	population			the treatment
_		interventions				the situation	including no			of the disease)
_		that might be				should	intervention or			
_		replaced by				the new	interventions			
_		the new one)				technology	used in			
_						not be	different			
_						adopted)	conditions)			

Foroutan et al

Table 2 (Continued)	nued)									
BIA primary	BIA	ISPOR	Canada	Belgium	France	Ireland	Poland	UK (2017)	Australia	Brazil (2012)
elements	secondary elements	(2014)	(2007)	(2012)	(2018)	(2018)	(2016)		(2016)	
	New	Yes (the	Yes (new	Yes	Yes (scenarios	Yes (new	Yes (reflects			Yes (cost
	intervention	introduction	drug scenario		with the	technology	the market			of each
	mix	of a new	is forecast		intervention	scenario,	after the			intervention
		intervention	version of		under study)	where the	introduction			included in the
		sets in motion	the current			new drug is	of the new			analysis will
		various	market with			adopted)	technology)			reflect the cost
		marketplace	introduction							of the entire
		dynamics,	of the new							therapeutic
		including	drug)							package
		product								associated
		substitution								with that
		and possibly								intervention)
		market								
		expansion)								
Costs and										
outcomes										
	Direct cost							Yes		
	consequence of									
	implementing									
	NICE									
	guidelines									
										(Continued)

elements	BIA secondary elements	(2014)	Canada (2007)	Belgium (2012)	France (2018)	lreland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Cost of the current and new intervention mix is determined by multiplying the budget holder's price for each intervention by proportion of the eligible population using that intervention and by the number of people in the eligible population Arrual	ده ۲	Yes (treatment strategy-based approach) Yes		Xes	Kes Kes	Les			
	Actual acquisition cost of the intervention for the budget holder includes any discounts, rebates, or other adjustments	ຍ -	es			e e				

I able 2 (continued)	uea)									
BIA primary elements	BIA secondary	(2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	elements									
	Opportunity	Yes				Yes	Yes (the cost			
	costs are the						of additional			
	costs that						outlays in			
	arise when						the health			
	implementing						care system,			
	the technology						related to the			
	or clinical						implementation			
	guidelines that						of the assessed			
	might not being						technology)			
	reflected in the									
	"actual costs"									
	at the time									
	of doing BIA									
	analysis									
	The costs	Yes	Yes (direct			Yes (drug	Yes (actual	Yes	Yes (direct	Yes (costs
	included should		drug cost)			administration	payments and		drug cost)	of the new
	he limited to)			costs the	actual cavings		` >	drug and
	direct costs					costs, une	actual savilies			those directly
						cost of drug				
	associated with					wastage	public payer/			associated
	the technology					and the	patient; taking			with its use,
	that will accrue					cost of drug	into account			as adjuvant
	to the relevant					monitoring)	the existing			medications or
	payer(s)						risk sharing			treatment of
							schemes)			adverse events)
	Cost of clinical	Yes	No	No (health		Yes (efficacy,		Yes (direct		
	outcomes			outcomes are		effectiveness,		clinical		
	and disease			not included;		and safety,		consequences)		
	complication			however cost		cost offsets)				
				consequences						
				of health						
				outcome, eg,						
				treatment						
				cost of						
				adverse						
				events, are						
				included)						
										(Continued)

elements	BIA secondary elements	(2014)	Canada (2007)	Belgium (2012)	France (2018)	(2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Cost of health care utilization	Yes	°Z	Yes (eg, cost of		Yes (cost offsets)	Yes			
	(eg, hospital days or physician visits)			treatment of adverse drug reactions)						
	Indirect costs:	No (should	No	Maybe (can		Q		Yes (eg,		No
	the impact	not be		be quantified				productivity		
	of the new	included		in a separate				cost)		
	intervention on	routinely		analysis)						
	productivity,	in a BIA								
	social services,	[except for								
	and other costs	the private								
	outside the	payers or								
	health care	employers])								
	system									
	Cost of	Yes				Yes	Yes			Yes
	supplies:									
	the analytic									
	tramework									
	should allow									
	for cost-									
	relevant									
	details of how									
	accompanying									
	devices for									
	the proposed									
	medication are									
	used									
	The annual					Yes				
	depreciation									
	of any capital									
	costs should be									
	included in the									
	analysis									
	Labor costs					Yes	Yes (eg, staff training cost)			
	Value-added					Yes	D			

Foroutan et al

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Proposed drug cost based	Yes	Yes			Yes (technology	Yes	Yes	Yes (changes in the number	Yes (per patient. per
	on unit drug					cost)			of units	time period)
	price and								dispensed and	
	average dose								costs over the	
	for average								time horizon)	
	duration of time									
	The BIA should	Yes								
	also estimate									
	the impact of									
	adherence or									
	persistence on									
	intervention									
	effectiveness									
	and safety if									
	condition-									
	related costs									
	are included in									
	ure DIA			:					:	
	Calculate both			Yes					Yes	
	the global									
	budget impact									
	and separately									
	the budget									
	impact for the									
	different health									
	care payers									
	(this implies									
	that potential									
	transfers									
	of budgets									
	between									
	different levels									
	of governments									
	and/or									
	nationts)									

	~ .									
BIA primary	BIA		Canada	Belgium	France	Ireland	Poland	UK (2017)	Australia	Brazil (2012)
elements	secondary	(2014)	(2007)	(2012)	(2018)	(2018)	(2016)		(2016)	
	elements									
	Application of									Yes
	the therapeutic									
	equivalence									
	method in the									
	comparison									
	of costs is									
	recommended									
Time horizon										
	BIAs should	I-5 years	3 years	3 years	3-5 years	5 years	2 years	5 years	6 years	I-5 years
	be presented									(subjected to
	for the time									budget holder's
	horizons of									needs)
	relevance to									
	the budget									
	holder									
Modeling										
	Modeling may	Yes (if an		Yes	Yes	Yes (based		Yes	Yes	Yes
	be needed to	economic			(according	on the good				
	calculate the	evaluation			to the	modeling				
	budget impact	was			characteristics	practice)				
	for bringing	performed,			and the					
	together the	the BIA			management					
	best available	model should			of the disease					
	data from	be consistent			of interest in					
	different	with the			France)					
	sources	clinical and								
		economic								
		assumptions								
		in EE)								
	Assumptions	Yes (the		Yes		Yes		Yes	Yes	
	should be the	justified								
	same as EE	comparator in								
		an economic								
		evaluation								
		may be								
		different								
		from the								
		comparator								
		in the BIA)								

836

(Continued)

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	The computing framework for a BIA can be a simple cost calculator programmed in an Excel-based spreadsheet	Yes	Yes	≺es	Maybe (transparent and accessible to the decision maker)			Yes (a resource impact template is an Excel spreadsheet)	Yes	X es
	More complicated software	Yes		Yes (decision tree, Markov model)		No (simplest design)				Yes (decision tree, Markov models, discrete event simulation)
Handling uncertainty and scenario analyses										
	Sensitivity analysis: parameter uncertainty in the input values	Yes	Yes		Yes	Yes	Yes			Yes
	One-way and/ or multi-way sensitivity analysis, analysis of extremes	Yes	Yes		Yes	Yes	Yes			
	PSA is recommended in BIA		°Z	Yes		Yes				

ClinicoEconomics and Outcomes Research 2018:10

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Scenario	Yes		Yes	Yes	Yes			Yes	
	analysis:									
	uncertainty									
	introduced									
	by the									
	assumptions									
	made in									
	framing the BIA									
	Important	Yes	Yes			Yes	Yes (population		Yes	Yes
	parameters to						size [eg,			
	be assessed in						the degree			
	the sensitivity						of possible			
	and scenario						abuse], costs			
	analyses						of use and			
	have been						reimbursement			
	provided in the						conditions)			
	guidelines									
	Describe the								Yes	
	direction and									
	magnitude of									
	the impact of									
	uncertainty									
	on the overall									
	estimates									

Understand between <th></th> <th>IIA</th> <th>ISPOR</th> <th>C-nada</th> <th></th> <th>_</th> <th></th> <th></th> <th></th> <th>:</th> <th></th>		IIA	ISPOR	C-nada		_				:	
state Col14) Col13 Col13 Col13 Col15 Col16 res rescentary Ves Col13 Col13 Col13 Col15 Col16 res rescentary Ves Ves Col13 Col13 Col15 Col15 res res res res res res res res res res res Yes Yes Yes Yes Yes Yes res res Yes Yes Yes Yes Yes Yes resolution Yes Yes Yes			:)	Caliaua	Beigium	France	Ireland	Poland	UK (2017)	Australia	Brazil (2012)
nte i i i i i i i i A tempt bould ferrates Matempt Yes Yes i i i i A tempt bould ferrates for (recesting for (recesting for (recesting i <th></th> <th>econdary lements</th> <th>(2014)</th> <th>(2007)</th> <th>(2012)</th> <th>(2018)</th> <th>(2018)</th> <th>(2016)</th> <th></th> <th>(2016)</th> <th></th>		econdary lements	(2014)	(2007)	(2012)	(2018)	(2018)	(2016)		(2016)	
A attention for object wates of the desired of the desired of the currency to the disc. Ves Ves Ves (n certain currency) Ves Ves Ves In the currency to the disc. Ves Ves Ves Ves Ves Ves In the currency to the disc. Ves Ves Ves Ves Ves Ves In the currency to the currency Ves Ves Ves Ves In the currency to the currency to the currency to the currency to the currency to the currency to the currency Ves Ves Ves Ves Ves In the process of the currency to currency to currency to currency Ves Ves Ves Ves Ves Ves In the process of the currency to currency No Ves Ves Ves Ves Ves In the process of the currency No Ves Ves Ves Ves Ves In the process of the currency No Ves Ves Ves Ves Ves In the process of the currency No Ves Ves Ves Ves Ves Ves </td <td>< ₽</td> <td></td>	< ₽										
increasing transpering thanges in the currency thanges in the currency thanges in the currency thange in the currency thange in the currency the currency set of the information inform the bugges to lead the currency set of the information inform the bugges to lead the currency set of the information inform the bugges to lead the currency set of the information inform the bugges to lead information inform the bugges to lead information inform the bugges to lead information informatio	7	in attempt	Yes	Yes			Yes (in certain				Yes (in certain
Crif for creating the value of the currency used the line boot the li	5	hould be made					circumstance)				circumstance)
thanges in the varies of the currency before the currency the currency before the currency the currency before the currency before Now or the fink before the currency before the currency before the currency before Now or the fink before the currency before the currency before the currency before Now or the fink before the currency before the currency before the currency before Now of the fink before the currency before the currency before the currency before Now of the value the currency buget hole's decisions the value the currency before No the value the value the value No the value the value No the value the value Information the value Informat	fc	or forecasting									
the value of the untervalue over the Biols the untervalue over the Biols the untervalue over the Biols the untervalue over the Biols the untervalue over the Biols over the Biols the untervalue over the Biols the untervalue over the Biols the untervalue over the Biols the untervalue over the Biols Discounding is required the onputing the untervalue over the Biols the onput disc the undip to disc and hput disc the onput disc the undip to disc and hput disc the onput disc the undip to disc the undip to disc and hput disc the onput disc the undip to disc the undip to disc analysis the the undip to disc the undip to disc the onput disc the undip to disc the undip to disc the one undip to disc the prosented the undip to disc Interval the procestion to interval the one undip to disc the one undip to disc the one undip to disc Interval the one undip to disc	c	hanges in									
the currency be currency be currency be currency be currenting is required the currency be currenting is required Yes Yes Yes Yes The computing required Yes Yes Yes Yes Yes Yes The process of required No Yes Yes Yes Yes Yes The process of required Yes Yes Yes Yes Yes Yes Value of the required Yes Yes Yes Yes Yes Yes Value of the required Yes Yes Yes Yes Yes Yes Value of the required Yes Yes Yes Yes Yes Yes Value of the required Yes Yes Yes Yes Yes Yes Value of the required Yes Yes Yes Yes Yes Yes <td>t</td> <td>he value of</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	t	he value of									
verothe BIA verothe BIA horton horton horton browning is reconting is Yes rection Yes reconting information Yes rection Yes	t	he currency									
over the time broritoring is recurring is required Yes Yes Yes Yes Disconting is required Yes Yes Yes Yes Disconting is required Yes Yes Yes Yes The computing required Yes Yes Yes Yes The computing required Yes Yes Yes Yes The computing required Yes Yes Yes Yes The required Yes Yes Yes Yes The required Yes Yes Yes Yes Information Yes Yes Yes Yes <	ï	sed the BIA									
Incrotion Incroting Yes Yes<	Ô	ver the time									
Discontingis Yes Yes <t< td=""><td>h</td><td>orizon</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	h	orizon									
generally not required Release in the required Release in the intervence Release in the required Release in the remplate Release in th		Discounting is	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
required required required required required The computing Yes Yes Yes Yes Yes Transwork and input data Yes Yes Yes Yes and input data Sh must be Yes Yes Yes Yes Sh must be Sh must be Yes Yes Yes Yes Sh must be Sh must be Yes Yes Yes Yes Used for a Bh must be Yes Yes Yes Yes B must be Sh must be Yes Yes Yes Yes D used for a No No Yes Yes Yes D use for on sufficienty valid No Yes Yes Yes D use for on sufficienty valid Yes Yes Yes Yes D use for on sufficienty valid No Yes Yes Yes D use for on sufficienty valid Yes Yes Yes Yes D use for on sufficienty No Yes Yes Yes D use for on sufficienty Yes Yes Yes Yes Value of the Yes Yes Yes Yes Value	<u></u>	enerally not									
Image: state of the computing transmork. Yes (face transmork. Yes	LE	equired									
mputingYesYesYesYesYesYesorkorkvalidity)YesYesYesYesorkvalidity)YesYesYesYesraraYesYesYesYesraraYesYesYesYesraNoYesYesYesYesblder'sNoYesYesYesbrestYesYesYesYesfitheYesYesYesYesoredYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesorYesYesYesYesOrYesYesYesYesOrYesYesYesYesOrYesYesYesYesOrYes <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>											
ork validity) tr data ra ra st be nity valid biby bib	μ μ	he computing	Yes	Yes	Yes (face	Yes	Yes			Yes (the	Yes
ut data ra st be ntj valid bijy the holder's ms sces of holder's bolder's holder's holder's holder's holder's holder's holder's holder's holder's sces of holder's holder's sces of holder's hol	fr	amework			validity)					template	
ra st be nty valid biy the holder's holder's ns scess of adion is action f the sche d d d tion s (the extra llection oved n)	ar	nd input data								workbook	
st be rty valid iby the holder's ns scss of dation is dation is the holder's ns scss of dation is dation is oceanded ocumented	'n	sed for a								enables the	
nty valid nty valid nty valid ib)y ib)y the ib)y the holder's No ns Yes ocess of No dation is No dation is No dation is No ocess of No ocess of No ocess of No ocest of No ocest of No ocest of No oced Yes nn) Ocentrated)	ā	A must be								PBAC to	
liby the holder's ns cress of dation is dation is dation is fue tion s (the extra lection oved oved	SL	ufficiently valid								validate the	
the holder's holder's and the holder's and the holder's and the set of the back of the set of the s	tc	o credibly								presented	
holder's in the set of	Ë	Iform the								estimates)	
addition is a dation is of the fittee trian s (the extra extra extra extra oved on a dation oved a dation is (the extra		udget holder's ecisions									
dation is dation is fithe Yes trion solution the Yes oved oved oved		he process of		No			Yes				
d fithe Yes Yes I fithe the Yes or oved on the fithe the fithe or the fithe extra extra extra oved on the fithe fi	с р.	ne validation is				_	(should be				
of the trion s (the extra extra llection oved	LE	equired					documented)				
information analyses (the cost of extra data collection vs improved model precision)	>	alue of the		Yes							
analyses (the analyses (the cost of extra cost of extra data collection vs improved model precision)	Ë	lormation									
cost of extra cost of extra data collection vs improved model model precision) model	ar	nalyses (the									
data collection vs improved model precision)	ວັ 	ost of extra									
vs improved model precision)	q	ata collection									
model precision)	ν. V	s improved									
precision)	5	labor									
	Ē	recision)									

submit your manuscript www.dovepress.com
Dovepress

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	The		Yes		Yes					Yes
	programming									
	created by									
	the developer									
	of the budget									
	impact model									
	to perform									
	the analysis									
	(source code)									
	should be made									
	available for									
	review (on the									
	condition that									
	property rights									
	are respected)									
	Model code		Yes							
	should be									
	provided to									
	reviewers									
	Postmarket	Yes	Yes					Yes	Yes	
	reassessment:									
	the observed									
	costs in a									
	health plan									
	with the									
	current									
	interventions									
	should be									
	compared with									
	the initial-year									
	estimates from									
	a BIA									
	Quality							Yes (for all	Yes (quality	
	assurance and							resource	use of	
	publication							impact	medicines)	

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
Inputs and data sources										
	Recommended data sources	Yes	Yes		Yes	Yes		Yes (quite comprehensive list)		Yes
	Search strategy;						Yes			
	inclusion									
	criteria for									
	data selection									
	and source									
	selection;									
	strengths and									
	weaknesses									
	of the used									
	sources, and									
	methods of									
	analysis should									
	be presented									
	Use data	Yes	Yes			Maybe				Yes (health
	from another					(might not				systems
	jurisdiction					be realistic in				comparable to
	where the					Ireland)				the Brazilian
	intervention									system)
	has been									
	introduced									
	Use estimates	Yes								
	or expected									
	friar ket snar e									
	producer									
	Extrapolate	Yes	Yes							
	from									
	experience									
	on product									
	diffusion									
	with similar									
	interventions									
	In the budget									
	noider s setting									

BIA primary	BIA	ISPOR	Canada	Belgium	France	Ireland	Poland	UK (2017)	Australia	Brazil (2012)
elements	secondary elements	(2014)	(2007)	(2012)	(2018)	(2018)	(2016)		(2016)	
	Data could be	Yes	Yes			Yes				
	sourced from clinical trials									
	Unpublished	Yes	Yes			Yes	Yes (taking			Yes
	data sources,						into account			
	such as expert						the existing			
	panels						risk sharing			
	Original									Yes
	cost survey,									
	obtaining									
	primary data,									
	by sampling,									
	involving									
	interviews									
	with health									
	professionals									
	under study									
Presenting results										
	The estimated	Maybe (a	Only		Yes	Yes	Yes		Yes	
	annual	table should	incremental							
	total and	show the	impact							
	incremental	total and								
	budget impacts	disaggregated								
	should be	costs for each								
	reported	time period								
	separately for	reported in								
	each year of	the BIA)								
	the time frame									
	Results should					Yes				
	be reported in									
	terms of their									
	natural units									
	and financial									
	cost									

BIA primary elements	BIA secondary elements	ISPOR (2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	Introduction, study design	Yes (very detailed)	Yes (not described in			Yes (not described in				
	and methods,		detail)			detail)				
	results,									
	conclusions, and limitations									
	All results	Yes (results	Yes (results	Yes (results	Yes	Yes	Yes (results	Yes (results	Yes (according	
	should be	should be	should be	should be			should be	should be	to the PBS and	
	presented	presented in a	presented in a	presented in a			presented in a	presented in a	the RPBS, and	
	in their	disaggregated	disaggregated	disaggregated			disaggregated	disaggregated	for beneficiary	
	disaggregated	manner)	manner)	manner)			manner)	manner)	type)	
	and aggregated									
	forms for each									
	year of the									
	timeframe									
	Inclusion of	Yes								
	graphics and									
	figure of the									
	analytical									
	framework,									
	schematic									
	representation									
	of uncertainty									
	analyses	:					:			
	Table of	Yes					Yes			Yes
	assumptions,									
	tables of inputs									
	and outputs,									
	appendices, and									
	references									

BIA primary elements	BIA secondary	(2014)	Canada (2007)	Belgium (2012)	France (2018)	Ireland (2018)	Poland (2016)	UK (2017)	Australia (2016)	Brazil (2012)
	elements									
	The addition	Yes								Yes
	of relevant									
	appendices									
	to the main									
	report is									
	encouraged.									
	The appendices									
	may cover									
	literature									
	search									
	strategies,									
	evidence									
	summaries,									
	intermediate									
	results (eg,									
	of individual									
	Delphi panel									
	rounds, and									
	the names and									
	addresses of									
	participating									
	experts and									
	investigators)									
	Resource							Yes		
	impact									
	products:									
	resource									
	planner;									
	resource									
	impact reports									
	and templates;									
	resource									
	impact									
	statement									




Figure 2 A schematic list of BIA recommendations in the reviewed guidelines. Note: The positive and negative recommendations are illustrated in different colors.

Abbreviations: BIA, budget impact analysis; EE, economic evaluation; NICE, National Institute for Health and Care Excellence.

the NICE guidelines in the NHS.¹⁰ In Canada, the comparator definition is more market-oriented. According to the Canadian BIA guidelines, reference scenario is the current market-share distribution of all comparators without new drug, whereas new drug scenario is forecast market share of same comparators with the inclusion of the new drug.²⁶ Multidrug treatment (ie, treatment mix or set,¹⁴ treatment set,⁹ treatment mix,¹¹ and strategy-based treatment²⁶) rather than individual interventions is recommended in most of the guidelines.^{8,9,11,12,14,19,26}

Cost analysis

Ireland, France, Australia, Poland, ISPOR, Brazil and Canada consider costing based on multi-drug treatment strategy (including adjunct therapies).^{8,9,11,12,14,19,26} The BIA should, therefore, identify all medicines likely to be affected by the new drug.

Most of the guidelines agree on the fact that direct health care-related costs for the most relevant perspective should be included in the base-case, similar to the guidelines for economic evaluations.^{8-10,12-14,19} However, the Australian¹¹ and Canadian²⁶ BIA guidelines exclude the costs associated with changes in outcomes, costs associated with clinical consequences/complications (eg, adverse drug reactions), and resource utilization (eg, hospitalization, emergency room admission), while other guidelines suggest to review such nondrug related costs. In the latest version of the Irish guidelines, for pharmaceuticals, direct costs include the cost of the drug and any other drug-related costs (concomitant therapies, adverse events, and infusion-related costs such as consumables and staffing).8 The impact on indirect, nonhealth care-related costs (eg, productivity, transport, capacity, and workforce) are not usually included in a BIA base-case analysis, except for the NICE guidelines (Table 2).8,9,13,14




Figure 3 Time horizon recommended by nine reviewed guidelines. Note: A range of time horizon is illustrated (in different color) for the guidelines/countries, if applicable. Abbreviation: ISPOR, International Society for Pharmacoeconomics and Outcomes Research.

Other differences between BIA guidelines were related to the scope of costs (eg, costs related to personnel training, budget transfers between different governments and patients).^{8,9,13,14} According to the Irish, Polish, and ISPOR guidelines, it is important to consider additional resources that must be taken from the existing services when implementing a new technology, which are called "opportunity costs." Opportunity costs are the costs that arise when implementing the technology or clinical guidelines that might not being reflected in the "actual costs" at the time of doing BIA analysis.8,12,14 In the case of including condition-related costs (ie, health outcomes and resource use), the actual opportunity costs are relevant in the ISPOR guidelines. In such cases analysts may use cost accounting approaches if actual opportunity costs are not available for a particular jurisdiction.¹⁴ According to the Irish guidelines "actual costs" are cash payments which occur from implementing the technology or clinical practice guidelines.8 The BIA should clearly state which unit of analysis is adopted in measuring the outcomes. There are two possible units of analysis: per patient or episode of care. Specified interventions may range from once-daily, repeated, periodic, or continuous interventions; it needs to be clear the number of times or the length of time people might experience the intervention or how many treatment events might arise.8,11,19

Cost of the treatment should be adjusted to consider markups, discounts, inventory allowance,^{8,14,26} business-related costs to the pharmacy covered by the drug plans, and dispensing fees and patient copayments, as requested by drug plans in Canada.²⁶ In the Canadian BIA guidelines, drug prices can be obtained from provincial formulary websites, public drug plan databases, and manufacturers' market access department for preparing BIA reports.²⁶ There are also recommendations on how to deal with New Chemical Entities and generic drug prices for BIAs in the Canadian BIA guidelines.²⁶ In Australia, Pharmaceutical Benefits Advisory Committee (PBAC) also recommends "dispensed price for maximum amount" for BIA.¹¹ It is recommended that uncertainties regarding the drug reimbursement price should be targeted through a sensitivity analysis.²⁶

In the Irish guidelines, the value-added tax could be considered if applicable,⁸ and in the Belgian and Canadian BIA guidelines, protocol-driven costs should be excluded (eg, costs related to the patient enrollment process and additional laboratory tests specific to the clinical trial design).^{13,26} None of the guidelines recommends inflation and discount rates; however, in the Canadian, Brazilian, Irish, and ISPOR BIA guidelines, they are permitted in the certain circumstances and if there is justification for being included (eg, confirmed information on pricing policy, implementation of an approved new policy rule in the near future, or price changes after patent expiration).

Modeling

Transparency, validity, simple, and user-friendly design along with explicit definitions and assumptions are the most favorable features of a BIA model. It is recommended that the model be designed based on the projected disease condition and be flexible enough to capture long-term outcomes/costs in the chronic diseases.⁹ Similar to cost-effectiveness analyses, in the Belgian and Brazilian BIA guidelines, decision trees or Markov models can be helpful to be consistent with the economic evaluations.^{13,19} Most guidelines recommend using an Excel-based model (rather than more complicated software) to calculate the budget impact.^{9–11,14,19,26} This allows for extending the analysis to the appropriate time horizon and using different data sources. Face, internal, and external validities have to be checked and documented. The model validity and transparency could be assessed using recommendations provided by ISPOR and the Society for Medical Decision Making task force report.³⁰

Handling the uncertainty

Decreasing the uncertainty is an essential consideration in BIA. Although probabilistic sensitivity analysis is not recommended in the Canadian BIA guidelines, one-way, univariate deterministic sensitivity analysis or multivariate scenario analysis are acceptable for the most important variables such as prices, population and market shares.²⁶ Sensitivity analysis of data obtained from clinical trials,¹¹ drug dosage,²⁶ price,²⁶ and market data from other jurisdictions¹⁴ are also recommended.^{8,9,11,12,14,19,26}

Scenario analysis is recommended by Ireland, France, Australia, Belgium, and ISPOR.^{8,9,11,13,14} PBAC¹¹ has provided a very detailed list of recommended scenarios to be considered in reporting the budget impact results, eg, the effects of promotional efforts on prescriber and consumer behavior. Risk sharing agreements with the manufacturers and a more extended introduction phase for the proposed drug have also been recommended by the UK and Australia for managing uncertainty in early BIA results.^{10,11}

Input and data sources

National statistics and registries are recommended sources for epidemiologic data (eg, disease prevalence and incidence).^{8,9,12,14,19,26} The best sources for the claim-based and market research information are the payer database¹⁴ and the manufacturer's marketing department.^{14,26} In the Irish, ISPOR, Brazilian and Canadian guidelines, data from foreign markets are acceptable if local information are not available (Table 2).^{8,14,19,26} The BIA reports from manufacturers with clear supporting data could also be helpful.^{14,26} Consensus expert opinion is an option when market intelligence for forecasting the new drug market share is not available.^{8,12,14,19,26}

Reporting format

There are specific requirements for reporting the results in the reviewed guidelines. Newly updated guidelines have put more attention to the details and the manner BIA results are reported, mainly based on the policymakers' interest and requirements.

Total and incremental impact on the primary payer's budget should be presented in the Polish, Irish, French, and Australian guidelines.^{8,9,11,12} The Canadian guidelines only require the incremental impact on the annual budget.²⁶ Results should be both aggregated and disaggregated in each year of the time horizon in the Irish, French and Australian guidelines.^{8,9,11}

The budget impact can be presented in natural (eg, number of unpaid working days) and monetary units separately for the different health care payers.⁸ A table of assumptions, inputs, and outputs, a schematic representation of any uncertainty analyses (eg, Tornado diagram), appendices, and references should be included.^{9,14,19} Estimated financial implications for the health budget (other health sectors), the impact of uncertainty (quantify how precise are the results), activities to support the quality use of medicines, and postmarketing surveillance amendments are recommended by PBAC.¹¹ In their new resource impact assessment (RIA) manual, NICE classifies results as "substantial" if the implementation of a single recommendation in the UK costs higher than a specific threshold.¹⁰

NICE recommends publishing the resource planner, a word file of resource impact reports, resource impact statements, quality assurance and publication, as well as making postpublication amendments. RIA results should be published at the same time as NICE evidence-based guidelines and performed in parallel with economic evaluations.¹⁰

Discussion

In the present review, we identified BIA guidelines from Ireland, France, UK, Australia, Poland, Belgium, ISPOR, Brazil and Canada reviewed and all their recommendations related to the analytical model structure, input and data sources, and reporting format of BIAs.^{8–14,19,26} It is the first peer-reviewed evidence in the health literature in which a systematic review of national and transnational BIA guidelines was published as robust and comprehensive basis for the future research.

There are some similarities in guidelines recommendations (eg, using drug-related direct costs from the primary payer's perspective, top-down or bottom-up approaches for population assessment, simple [not complicated] modeling techniques, and deterministic sensitivity analysis as the minimum requirements for a BIA base-case analysis). Differences between guidelines were related to number, scope, and direction (yes/no) of recommendations (eg,

inclusion of off-label indications, indirect costs, clinical outcomes, and health care resource utilization; duration of time horizon; dealing with uncertainty [eg, deterministic analysis vs PSA], and reporting format). Moreover, there are differences in the terminologies which are used in different guidelines/countries for defining specific concepts in designing a BIA (eg, multidrug treatment in assessing the comparators, target population definition such as "open population", or cost offsets).

Some guidelines were closely aligned in their recommendations (eg, French, Australian, Belgian, and ISPOR BIA guidelines), while others had included more countryspecific recommendations (eg, Canada, Australia, and the UK). In some guidelines/countries such as ISPOR, UK, Belgium, Ireland, and Australia, if an economic evaluation was performed, the BIA model should be consistent with the clinical and economic assumptions in economic evaluation. In the UK, BIA is called RIA and the estimation of costs and savings is based on direct consequence of implementing NICE guidelines (not just drug comparators).¹⁰

The results of our review are similar to the French literature review9 of BIA guidelines in terms of key aspects in designing BIA. However, our review used BIA categories more aligned with the ISPOR BIA guidelines.14 The literature review that was conducted as part of the Belgian guidelines was not published with sufficient detail,¹³ and the literature review results in the French guidelines were summarized in an aggregated format.9 Thus, there were insufficient details to provide a complete taxonomy of BIA guideline recommendations. A previous Canadian BIA literature review²⁶ included the older versions of the Polish (2004), Australian (2002), and ISPOR (2007) BIA guidelines. Our literature review was different in terms of 1) the review design (systematic), 2) the scope (focused on only BIA guidelines recommendations), 3) inclusion criteria (all BIA guidelines published since 1998, excluding any versions that were replaced by newer updates), and 4) reporting format (applicable details for future research).

The present review is the most recent systematic review of published national and transnational BIA guidelines that have been created or updated since 1998. A potential limitation of this study includes having only one reviewer for the level 1 (title and abstract) screening which we believe that did not contribute to considerable bias. We did not include results from countries that simply adopt BIA guidelines from other jurisdictions (Germany, Thailand, USA, Scotland, and Wales) which might be considered a limitation in that it would underestimate the frequency of use for some recommendations. We also did not include published BIA methodologic papers as we were only interested in reviewing BIA guideline recommendations.

Conclusion

To maintain sustainability in financing the health care systems, it is increasingly important to improve informed pricing and reimbursement decision making at national and transnational levels. Our literature review showed that over last 20 years, countries have become actively interested in comprehensive financial and economic evaluations and have tried to keep their BIA guidelines updated. Through a systematic review of national and transnational BIA guidelines published or updated since 1998 following Mauskopf's1 publication, we provided a full list (not a summary) of the details for conducting a standard pharmaceutical BIA in accordance with the most up-to-date national and transnational BIA guidelines recommendations. The remaining challenge is how to embrace the heterogeneity of recommendations and terminologies that is evident across different guidelines. Further research is required to analysis each countries' pharmaceutical financing system in more detail to assess any true relationship between country-specific health care parameters and BIA recommendations. The results of this review can be a starting point for countries who are initiating the development of national standard BIA guidelines based on their pharmaceutical reimbursement requirements. The present review can provide useful practical methodological information for BIA users and producers and provide a contribution to the future research in the field of pharmaceutical BIA.

Acknowledgment

The authors appreciate the contributions made by Arash Foroutan (second reviewer for level 2 screening) and Fergal Mills (Innomar Strategies) to this project.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Mauskopf J. Prevalence-Based Economic Evaluation. *Value in Health*. 1998;1(4):251–259.
- Trueman P, Drummond MF, Hutton J. Developing Guidance for Budget Impact Analysis. *Pharmacoeconomics* 2001;19(6):609–621.
- Orlewska E, Mierzejewski P. Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries. *Value in Health*. 2004;7(1).
- Patented Medicine Prices Review Board. Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. 2007; http://www.pmprb-cepmb.gc.ca/cmfiles/ bia-may0738lvv-5282007-5906.pdf. Accessed Feb 1st, 2018.

- Mauskopf J, Sullivan S, Annemans L, et al. Principles of Good Practice for Budget Impact Analysis: Report of the ISPOR Task Force on Good Research Practices—Budget Impact Analysis. *Value in health*. 2007;10(5).
- Institute for Quality and Efficiency in Health Care (IQWiG). Methods for assessment of the relation of benefits to costs in the German statutory health care system. 2008; http://www.rees-france.com/en/article. php3?id_article=523 Accessed Jan 27, 2018.
- Collège des Économistes de la Santé (CES). Guide méthodologique pour la mise en place d'une analyse d'impact budgetaire 2008; http:// www.ces-asso.org/docs/Rapport_AIB.pdf. Accessed Feb 20, 2018.
- Health Information and Quality Authority. Guidelines for the Budget Impact Analysis of Health Technologies in Ireland 2018; https:// www.hiqa.ie/reports-and-publications/health-technology-assessment/ guidelines-budget-impact-analysis-health. Accessed Jan 27, 2018.
- 9. Ghabri S, Autin E, Poullie AI, Josselin JM. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA). *Pharmacoeconomics*. 2017.
- National Institute for Health and Care Excellence. Assessing resource impact process. 2017; https://www.nice.org.uk/about/what-we-do/intopractice/resource-impact-assessment. Accessed Jan 27th, 2018.
- Department of health, Australian government. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Comittee. *Pharmaceutical Benefits Advisory Comittee guidelines* 2016; https:// pbac.pbs.gov.au/. Accessed Jan 27th, 2018.
- The Agency for Health Technology Assessment and Tariff System (Polish). Health Technology Assessment Guidelines. 2016; http://www. aotm.gov.pl/www/wp-content/uploads/wytyczne_hta/2016/20161104_ HTA_Guidelines_AOTMiT.pdf. Accessed Jan 27th, 2018.
- Neyt M, Cleemput I, Van De Sande S, Thiry N. Belgian guidelines for budget impact analyses. *Acta Clinica Belgica: International Journal* of Clinical and Laboratory Medicine. 2015;70(3):175–180.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis

 Principles of good practice: Report of the ISPOR 2012 budget impact analysis good practice II task force. *Value in Health*. 2014;17(1):5–14.
- Foroutan N, Jamshidi HR, Salamzadeh J, Foroutan A, Rasekh H. PRM18 Conducting Pharmaceutical Budget Impact Analyses in Iran: In Accordance With ISPOR Task Force Report on Good Practice for Budget Impact Analysis. *Value in Health*. 2012;15(7):A463.
- Foroutan N, Rasekh HR, Salamzadeh J, Jamshidi HR, Nafar M. Budget impact analysis of conversion from cyclosporine to sirolimus as immunosuppressive medication in renal transplantation therapy. *ClinicoEconomics and outcomes research*: CEOR. 2013;5:545–553.
- Jamshidi HR, Foroutan N, Salamzadeh J. "Budget Impact Analyses": A Practical Policy Making Tool for Drug Reimbursement Decisions. *Iranian Journal of Pharmaceutical Research*: IJPR. 2014;13(3):1105–1109.

- Leelahavarong P. Budget impact analysis. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2014;97 Suppl 5: S65–71.
- Ferreira-Da-Silva AL, Ribeiro RA, Santos VC, Elias FT, d'Oliveira AL, Polanczyk CA. [Guidelines for budget impact analysis of health technologies in Brazil]. *Cadernos de saude publica*. 2012;28(7): 1223–1238.
- Nanavaty M, Gala S, Nyandege A, Ramesh V, Mwamburi M. Understanding Health Technology Assessment (HTA) Bodies in Major Latin-American (LATAM) Markets: Systematic Evaluation in 5 Latam Countries. *Value in Health*. 2016;19(7):A491.
- 21. Faleiros DR, Alvares J, Almeida AM, et al. Budget impact analysis of medicines: updated systematic review and implications. *Expert review of pharmacoeconomics & outcomes research*. 2016;16(2):257–266.
- Garattini L, van de Vooren K. Budget impact analysis in economic evaluation: a proposal for a clearer definition. *The European journal of health economics: HEPAC: health economics in prevention and care*. 2011;12(6):499–502.
- Mauskopf J, Earnshaw S. A Methodological Review of US Budget-Impact Models for New Drugs. *PharmacoEconomics*. 2016;34(11): 1111–1131.
- Orlewska E, Gulacsi L. Budget-impact analyses: a critical review of published studies. *Pharmacoeconomics*. 2009;27(10):807–827.
- van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. *Appl Health Econ Health Policy*. 2014;12(1):33–40.
- Marshall DA, Douglas PR, Drummond MF, et al. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. *Pharmacoeconomics*. 2008;26(6):477-495.
- 27. Academy of Managed Care Pharmacy. A Format for Submission of Clinical and Economic Evidence of Pharmaceuticals in Support of Formulary Consideration Version 4. 2016; http://www.amcp.org/ practice-resources/amcp-format-formulary-submissions.pdf. Accessed Jan 27, 2018.
- All Wales Medicines Strategy Group. Form B Guidance notes. 2016; http://www.awmsg.org/docs/awmsg/appraisaldocs/inforandforms/ Form%20B%20guidance%20notes.pdf. Accessed Feb 1st, 2018.
- 29. Scottish Medicine Consortium. Guidance to manufacturers for completion of new product assessment form (NPAF). 2013; https:// www.scottishmedicines.org.uk/Submission_Process/Submission_guidance_and_forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. Accessed Feb 1st, 2018.
- Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. *Med Decis Making*. 2012;32(5):733-743. doi: 710.1177/0272989X12454579.

Search strategy MEDLINE:

Supplementary materials Supplementary material SI

Systematic literature review process

MEDLINE, EMBASE, Cochrane, EconLit, CINAHL, Business Source, Ovid HealthSTAR, and the gray literature including International Network for Agencies for Health Technology Assessment (INAHTA) and non-INAHTA members (eg, NICE, PHARMAC) as well as European network for health technology assessment (EUnetHTA), Health Technology Assessment International (HTAi), iHEA, and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) were searched using a combination of text words and Medical Subject Headings terms and synonyms of budget/financial analysis, guidelines, and methodology/modeling. The keywords used for the searches are as following:

Budget impact/budgetary impact/resource impact/financial impact analysis/assessment/studies	
I. "budget impact*".m_titl.	
2. "budgetary impact*".m_titl.	
3. budget impact analy*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, proto supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	col
4. budgetary impact analy*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	
5. budget impact stud*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, proto- supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	col
6. financial impact*.mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]	
7. "economic impact*".m_titl.	
8. "economic analy*".m_titl.	
Review; guidance; guidelines; methods	
 review.mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplement concept word, rare disease supplementary concept word, unique identifier, synonyms] 	ntary
10. limit 9 to "review articles."	
II. "Review Literature as Topic"/	
12. "review*".m_titl.	
13. "guideline*".m_titl.	
14. limit 13 to abstracts	
15. "guidance*".m_titl.	
16. limit 15 to abstracts	
17. Methods/	
18. "method*".m_titl.	
19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	
20. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18	
21. 19 and 20	
#HITs: 120	

The gray literature list

Websites of health technology assessment or regulatory agencies

Countries	Agencies
Inter/	International Network for Agencies for Health Technology Assessment (INAHTA); Health Technology Assessment
multinational	International (HTAi); International Society For Pharmacoeconomics and Outcomes Research (ISPOR); WHO Health
	Evidence Network; European Information Network on New and Changing Health Technologies (EUROSCAN); the
	University of Birmingham; National Horizon Scanning Centre; European network for health technology assessment
	(EUnetHTA)
Australia	Department of Health and Aging (https://pbac.pbs.gov.au/)
Austria	Institute of Technology Assessment (ITA); Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA)
Belgium	Federal Kenniscentrum voor de Gezendheidszorg (KCE)
Canada	Canadian Agency for Drugs and Technologies in Health (CADTH)
	Provincial drug plans:
	 http://www.health.gov.on.ca/en/pro/programs/drugs/drug_submissions/guideline_templates.aspx
	 https://www.ab.bluecross.ca/dbl/pdfs/bia-form.docx
	 https://www.gov.mb.ca/health/mdbif/sub.html
	http://www.inesss.qc.ca/fileadmin/doc/INESSS/Inscription_medicaments/Fiches_inscription/en/Submission_
	guidance_document.pdf
Republic of	National Health Development Research Center (NHDRC); Key Lab of Health Technology Assessment
China	
Denmark	Danish Centre for Evaluation and Health Technology Assessment (DCEHTA); Danish Institute for Health Services
	Research and Development (DSI)
Finland	Finnish Office for Health Care Technology and Assessment (FinOHTA)
France	L'Agence Nationale d'Accréditation et d'Evaluation en Santé (ANAES); Ministere de la Santé, de la Famille, et des
	Personnes handicappés; Committee for Evaluation and Diffusion of Innovative Technologies (CEDIT); French National
	Authority for Health (HAS) Department of Economics and Public Health Assessment
Germany	German Institute for Medical Documentation and Information (DIMDI)
Israel	Israel Center for Technology Assessment in Health Care (ICTAHC)
Netherlands	College voor Zorgverzekeringen/Health Care Insurance Board (CVZ); Health Council of the Netherlands
New Zealand	New Zealand Health Technology Assessment Clearing House for Health Outcomes and Health Technology
	Assessment (NZHTA)
Norway	Norwegian Centre for Health Technology Assessment (SMM)
Poland	Agency for Health Technology Assessment (AHTAPol)
Sweden	Centre for Medical Technology Assessment (CMT); Swedish Council on Technology Assessment in Health Care
	(SBU)
Switzerland	Swiss Network for Health Technology Assessment; Institute for Innovation and Valuation in Health Care (INNOVAL)
Thailand	Health Intervention and Technology Assessment Program (HiTAP)/International Health Policy Program (iHPP)
UK	National Health System (NHS)
	National Institute for Clinical Excellence (NICE)
	https://www.nice.org.uk/about/what-we-do/into-practice/resource-impact-assessment
	 https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/
	budget-impact-test
	 https://www.nice.org.uk/about/what-we-do/into-practice/forward-planner
	 https://www.nice.org.uk/about/what-we-do/into-practice/forward-planner#view
USA	Agency for Healthcare Research and Quality (AHRQ); ECRI Institute; Institute for Clinical Systems Improvement
	(ICSI); Blue Cross and Blue Shield Association's Technology Evaluation Center (TEC)

Supplementary material S2

Countries with developed budget impact analysis (BIA) guidelines and the types of drug programs where they are applied.

- In Australia, there is a government-run Pharmaceutical Benefits Scheme that subsidizes prescription medication, and there is a copayment for patients at the point of dispensing.¹ The BIA guidelines as a part of the Australian guidelines on the preparation of new drug submissions to Pharmaceutical Benefits Advisory Committee (PBAC) (2016) is the first full revision of PBAC guidelines since 2006. After 2010, any recommendation by PBAC that has a financial impact on the Federal government's budget is reviewed by the cabinet.² There is a close relationship between the estimated financial impact of a drug on the Australian drug budget and the rate of PBAC positive recommendations for reimbursement.³
- 2. Belgium has a Bismarck-type social insurance system (multipayer) in which the insurers, called Sickness Funds, are financed by both employers and employees.⁴ In Belgium, since 2002, Health Care Knowledge Centre (KCE) under the supervision of the Minister of Public Health and Social Affairs is in charge of conducting studies that support the political decision making on health care and health insurance.⁵ The Belgian guidelines for economic evaluations now include guidance for a BIA in an updated version (2015). The Belgian official Health Technology Assessment institute, KCE, and Belgian stakeholders from both government and industry contributed to improving their recent national economic evaluations and BIA guideline.⁵
- 3. In Brazil, the Unified Health System provides free universal care for all Brazilians as well as vaccinations and pre-natal care. A highly decentralized system has led to complex patterns of funding and service provision with the Federal, State, and Municipal governments involved. Brazil's system remains highly privatized with the private sector receiving substantial funds from all levels of government.6 Brazil (Ministry of Health [CONITEC]) has been developing the necessary analytical instruments for the evaluation of new technologies for health. In this context, the development of national recommendations for budget impact studies in the health area became more important. The methodology for the development of budgetary impact studies in the health area was adapted to the Brazilian needs, through several presentation and discussion sessions among the professionals of the institutions involved.7

- 4. Canada is an example of a "National Health Insurance" model. Canada's publicly funded health care system is called "Medicare" in which ten provincial and three territorial health care insurance plans share roles and responsibilities for health care services with the Federal government.8 Drug benefit funding is primarily a composite of provincial/territorial governments and private insurance programs. Federally, the Patented Medicine Prices Review Board sets ex-factory price ceilings for patented medications. Although a BIA had been required to be submitted to most provincial public drug plans in the 1990s, before 2007, there was no standardized method of conducting a BIA in Canada. In 2005, Patented Medicine Prices Review Board initiated the development of the Canadian BIA Guidelines on behalf of the National Prescription Drug Utilization Information System, and this was published in 2007.9
- 5. In France, the pharmaceutical reimbursement decisionmaking process consists of two steps: 1) the technical assessment by French National Authority for Health La Haute Autorité de Santé (HAS) and 2) enlisting the drug with price-fixing by the "health care products pricing committee" of the Ministry of Health (Comité Economique des Produits de Santé [CEPS]).¹⁰ Since January 2016, cost-effectiveness analysis and BIAs are required to be submitted by manufacturers to HAS and CEPS for highly specialized medicines with an expected 2-year sales revenue more than €50 million.¹¹ In France, BIA for new drug submissions should be prepared for the French statutory social insurance scheme. HAS updated the French BIA guidelines for new drug submissions in December 2017, however, it is not still clear that how BIA results would be applied in the reimbursement price negotiation process.
- 6. The Republic of Ireland has a new NHS which was launched in 2005 and is controlled by the Health Service Executive.¹² The Irish "Health Information and Quality Authority" (The Authority) has the responsibility to evaluate the clinical and cost-effectiveness of health technologies, and provides evidence-based reports to the Minister of Health and Health Service Executive and develops guidelines for doing HTA in Ireland. The latest updated version of the Irish BIA guidelines on health technologies was published by The Authority in 2018.¹³
- 7. Health care in Poland is primarily financed by the National Health Fund (Narodowy Fundusz Zdrowia) and state budget or local government budgets. The state budget plays a complementary role to National Health Fund in the system. The primary role of the local governments is

to ensure access to the services, mostly by performing ownership functions toward health care institutions. In Poland, the BIA guidelines are a part of the latest updated Health Technology Assessment guidelines which initially issued by the Agency for Health Technology Assessment and Tariff System in 2007 and were updated in 2009 and 2016.¹⁴

8. National Health Service (NHS) in the United Kingdom is an example of a single-payer health care system for a country. In the UK, the NHS institution in England and Wales pays for medicines if NICE provides a favorable recommendation. NICE published their updated guidelines on the resource impact (budget impact) assessment process on May 2017. It is proposed that a cap called "budget impact test"15 of £20 million, in any of the first 3 years, be considered to signal the need for negotiation with manufacturers for special arrangements to better manage the introduction of new technologies recommended by NICE.¹⁶ Moreover, NICE has recently proposed a Fast Track technology Appraisal process for the new technologies which fall below an incremental cost-effectiveness ratio of £10,000 per quality adjusted life years. The budget impact test would be removed as a criterion for entry into the Fast Track Technology Appraisal process.^{16,17}

References

- 1. The Guardian. Four healthcare systems divided by the English language: Australia, Canada and Ireland have universal healthcare systems, although run on different lines to Britain's NHS. And then there is the USA [press release]. London: The Guardian; 2011 [June 7].
- 2. Ghabri S, Mauskopf J. The use of budget impact analysis in the economic evaluation of new medicines in Australia, England, France and the United States: relationship to cost-effectiveness analysis and methodological challenges. *The European Journal of Health Economics*. 2017.
- Mauskopf J, Chirila C, Masaquel C, et al. Relationship between financial impact and coverage of drugs in Australia. *International journal* of technology assessment in health care. 2013;29(1):92–100.
- 4. The Belgian Health Care Knowledge Centre. *Drug Reimbursement Systems: International Comparison and Policy Recommendations, KCE reports 147C.* Brussels, Belgium: The Belgian Health Care Knowledge Centre; 2010. Available from: https://kce.fgov.be/sites/default/files/atoms/files/KCE_147C_Drug_reimbursement_systems_4.pdf. Accessed Mar 23, 2018.

- Neyt M, Cleemput I, Van De Sande S, Thiry N. Belgian guidelines for budget impact analyses. *Acta Clinica Belgica: International Journal* of Clinical and Laboratory Medicine. 2015;70(3):175–180.
- 6. The World Bank. *Brazil Health Financing Profile (English)*. Washington, DC: The World Bank; 2014.
- Ferreira-Da-Silva AL, Ribeiro RA, Santos VC, Elias FT, d'Oliveira AL, Polanczyk CA. [Guidelines for budget impact analysis of health technologies in Brazil]. *Cadernos de saude publica*. 2012;28(7):1223– 1238. Portuguese.
- Mossialos E, Wenzl M, Osborn R, Sarnak D. 2015 international profiles of health care systems. Canadian Agency for Drugs and Technologies in Health; 2016.
- Patented Medicine Prices Review Board. Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada. Canada: Patented Medicine Prices Review Board; 2007. Available from: http://www.pmprb-cepmb.gc.ca/cmfiles/ bia-may0738lvv-5282007-5906.pdf. Accessed February 1, 2018.
- France Pharmaceuticals. *Global Health Care Systems Road Map*; 2009. Available from: https://www.ispor.org/HTARoadMaps/France. asp#4. Accessed March 22, 2018.
- Ghabri S, Autin E, Poullie AI, Josselin JM. The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA). *Pharmacoeconomics*. 2018;36(4):407–417.
- 12. The Guardian. Four healthcare systems divided by the English language: Second part of Guardian Healthcare's guide to healthcare systems in English speaking countries: Republic of Ireland and United States of America [press release]. London: The Guardian; 2011 [June 7].
- Health Information and Quality Authority. Guidelines for the Budget Impact Analysis of Health Technologies in Ireland. Cork, Ireland: Health Information and Quality Authority; 2018. Available from: https:// www.hiqa.ie/reports-and-publications/health-technology-assessment/ guidelines-budget-impact-analysis-health. Accessed January 27, 2018.
- 14. The Agency for HealthTechnology Assessment and Tariff System. Health Technology Assessment Guidelines (Poland). Warsaw, Poland: The Agency for HealthTechnology Assessment and Tariff System; 2016. Available from: http://www.aotm.gov.pl/www/wp-content/ uploads/wytyczne_hta/2016/20161104_HTA_Guidelines_AOTMiT. pdf. Accessed January 27, 2018.
- 15. National Health Service. "Budget Impact Test" rather than "net budget impact" or threshold/cap to clarify to stakeholders that it is not the maximum funding by NHS. London: National Health Service.
- 16. National Institute for Health and Care Excellence. Proposals for changes to the arrangements for evaluating and funding drugs and other health technologies appraised through NICE's technology appraisal and highly specialised technologies programmes. London: National Institute for Health and Care Excellence; 2016.
- 17. National Institute for Health and Care Excellence. NICE and NHS England consultation on changes to the arrangements for evaluating and funding drugs and other health technologies assessed through NICE's technology appraisal and highly specialised technologies programmes. London: National Institute for Health and Care Excellence; 2017. Available from: https://www.nice.org.uk/Media/Default/About/what-we-do/ NICE-guidance/NICE-technology-appraisals/TA-HST-consultationresponse-paper-March-Board.pdf. Accessed March 26, 2018.

ClinicoEconomics and Outcomes Research

Publish your work in this journal

ClinicoEconomics and Outcomes Research is an international, peerreviewed open-access journal focusing on health technology assessment, pharmacoeconomics and outcomes research in the areas of diagnosis, medical devices, and clinical, surgical and pharmacological intervention. The economic impact of health policy and health systems organization also constitute important areas of coverage. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journal

Dovepress